Adjuvant chemotherapy for gastric cancer or not: A dilemma?

Journal of the National Cancer Institute

Volumn 100, Issue 6, 2008, Pages 376-377

  Wu, Aiwen ^a   Ji, Jiafu ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BIOLOGICAL MARKER; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER; ANTINEOPLASTIC AGENT; FLEP PROTOCOL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EDITORIAL; GASTRECTOMY; HUMAN; LYMPH NODE DISSECTION; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; STOMACH SURGERY; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; CHEMISTRY; ITALY; NOTE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR; TREATMENT OUTCOME; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; EPIRUBICIN; FLUOROURACIL; GASTRECTOMY; GREAT BRITAIN; HUMANS; ITALY; LEUCOVORIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 41449108274     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn055     Document Type: Editorial

References (15)

1. Di Costanzo F, Gasperoni S, Manzione L, et al.; On behalf of Italian Oncology Group for Cancer Research. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100(6):388-398.
2. Cocconi G, Carlini P, Gamboni A, et al.; Italian Oncology Group for Clinical Research. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol. 2003;14(8):1258-1263.
3. Nitti D, Wils J, Guimaraes Dos Santos J, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006;17(2):262-269.
4. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13(2):299-307.
5. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol. 2007;18(8):1354-1358.
6. Bouché O, Ychou M, Burtin P, et al.; Federation Francophone de Cancerologie Digestive Group. Adjuvant chemotherapy with 5- fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial. Ann Oncol. 2005;16(9):1488-1497.
7. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-1820.
8. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441-1447.
9. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35(7):1059-1064.
10. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11(7):837-843.
11. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168(11):597-608.
12. Ellenberg SS, Sun W. Adjuvant therapy for gastric cancer: how negative results can help patients. J Natl Cancer Inst. 2007;99(8):580-582.
13. Kim GP, Colangelo LH, Wieand HS, et al.; National Cancer Institute. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute - National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25(7):767-772.
14. Macdonald J, Smalley S, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-730.
15. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.